Back to Search Start Over

Surgically resected sarcomatoid carcinoma of the lung: a nationwide retrospective study in 2010.

Authors :
Kaseda, Kaoru
Asakura, Keisuke
Shintani, Yasushi
Okami, Jiro
Toyooka, Shinichi
Sato, Yukio
Watanabe, Shun-Ichi
Chida, Masayuki
Suzuki, Hidemi
Miyaoka, Etsuo
Yoshino, Ichiro
Date, Hiroshi
Source :
BMC Cancer; 8/2/2024, Vol. 24 Issue 1, p1-14, 14p
Publication Year :
2024

Abstract

Background: Sarcomatoid carcinoma of the lung is a rare histological type of non-small cell lung cancer with a poor prognosis. We aimed to investigate the clinicopathological characteristics and prognostic factors of surgically resected sarcomatoid carcinoma of the lung. Methods: We retrospectively reviewed 14999 patients who underwent surgical resection for non-small cell lung cancer accumulated by the Japanese Joint Committee of Lung Cancer Registry in 2010. Clinicopathological characteristics and survival were compared between the sarcomatoid carcinoma and other non-small cell cancer groups. The prognostic factors in the sarcomatoid carcinoma group were identified using a multivariate Cox proportional hazard model. Results: Patients with sarcomatoid carcinoma comprised 1.4% of all patients. The sarcomatoid carcinoma group demonstrated a more aggressive pathology with presentation at more advanced stages, requiring more frequent extensive surgical resections. The sarcomatoid carcinoma group had remarkably poorer overall and recurrence-free survival than the other non-small cell lung cancer group. Adjuvant chemotherapy was associated with improved survival for pathological stage II–III sarcomatoid carcinoma cases rather than for pathological stage I disease. In the multivariate analysis, larger tumor size, lymphatic permeation, and no adjuvant chemotherapy were associated with the sarcomatoid carcinoma group's overall and recurrence-free survival. Conclusions: Surgically resected sarcomatoid carcinoma of the lung has a higher aggressive and metastatic potential and a worse prognosis than other non-small cell lung cancers. Adjuvant chemotherapy, which was associated with enhanced survival in patients with pathological stage II–III of the disease, could be considered for treating patients with pathological stage II–III sarcomatoid carcinoma of the lung. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14712407
Volume :
24
Issue :
1
Database :
Complementary Index
Journal :
BMC Cancer
Publication Type :
Academic Journal
Accession number :
178807061
Full Text :
https://doi.org/10.1186/s12885-024-12728-2